Biosimilar Antibodies

Datopotamab Biosimilar – Anti-TACSTD2 mAb – Research Grade, ProteoGenix, PX-TA1653

Description of Datopotamab Biosimilar - Anti-TACSTD2 mAb - Research Grade Introduction Datopotamab Biosimilar, also known as Anti-TACSTD2 mAb, is a research grade monoclonal antibody that has been developed as a potential therapeutic agent for various diseases. In this article, we will discuss the structure, activity, and potential applications of Datopotamab Biosimilar. Structure of Datopotamab Biosimilar Datopotamab Biosimilar is a monoclonal antibody that specifically targets TACSTD2, also known as TROP2. It is a glycoprotein that is expressed on the surface of various types of cancer cells, including breast, lung, and pancreatic cancer. The antibody is a fully human IgG1 molecule, which means it is derived from human cells and has a constant region that is responsible for its therapeutic activity. The variable region of Datopotamab Biosimilar has been engineered to bind specifically to TACSTD2, allowing it to selectively target cancer cells. This is achieved through the use of hybridoma technology, where mouse B cells are fused with human myeloma cells to produce a hybrid cell line that can produce human antibodies. Activity of Datopotamab Biosimilar Datopotamab Biosimilar has been shown to have potent anti-tumor activity in preclinical studies. It works by binding to TACSTD2 on the surface of cancer cells, which leads to the activation of immune cells and subsequent destruction of the cancer cells. This mechanism of action is known as antibody-dependent cell-mediated cytotoxicity (ADCC). In addition to its direct anti-tumor activity, Datopotamab Biosimilar has also been shown to inhibit the growth and metastasis of cancer cells. This is achieved through the downregulation of key signaling pathways that are involved in cancer cell proliferation and migration. Applications of Datopotamab Biosimilar Datopotamab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Its potential applications include: Breast cancer: TACSTD2 is overexpressed in approximately 90% of breast cancer cases, making it a promising therapeutic target. Datopotamab Biosimilar has shown to be effective in inhibiting the growth and metastasis of breast cancer cells in preclinical studies. Lung cancer: TACSTD2 is also highly expressed in lung cancer, and Datopotamab Biosimilar has been shown to inhibit the growth and migration of lung cancer cells. It is currently being evaluated in clinical trials for the treatment of non-small cell lung cancer. Pancreatic cancer: Datopotamab Biosimilar has shown promising results in preclinical studies for the treatment of pancreatic cancer, which is known to have limited treatment options. It has been shown to inhibit the growth and metastasis of pancreatic cancer cells, and is currently being evaluated in clinical trials. In addition to these specific applications, Datopotamab Biosimilar has the potential to be used in combination with other therapies, such as chemotherapy and immunotherapy, to enhance their effectiveness and overcome treatment resistance. Conclusion Datopotamab Biosimilar is a research grade monoclonal antibody that has shown promising results in preclinical studies for the treatment of various types of cancer. Its specific targeting of TACSTD2 and its potent anti-tumor activity make it a promising therapeutic agent. With ongoing clinical trials, it has the potential to become a valuable addition to the treatment options for cancer patients. Keywords: antibody, therapeutic target, Datopotamab Biosimilar, Anti-TACSTD2 mAb, TACSTD2, cancer, preclinical studies, clinical trials, breast cancer, lung cancer, pancreatic cancer, ADCC, hybridoma technology

Demcizumab Biosimilar – Anti-DLL4 mAb – Research Grade, ProteoGenix, PX-TA1289

Description of Demcizumab Biosimilar - Anti-DLL4 mAb - Research Grade General information on Anti-DLL4 [Homo sapiens] (Demcizumab) Monoclonal Antibody Demcizumab is investigated for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.

Denosumab Biosimilar – Anti-RANKL mAb – Research Grade, ProteoGenix, PX-TA1018

Description of Denosumab Biosimilar - Anti-RANKL mAb - Research Grade General information about Denosumab Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides.This product is for research use only.

Depatuxizumab Biosimilar – Research Grade mAb, ProteoGenix, PX-TA1435-

Dezamizumab Biosimilar – Anti-APCS mAb – Research Grade, ProteoGenix, PX-TA1441

Description of Dezamizumab Biosimilar - Anti-APCS mAb - Research Grade General information on Anti-APCS[Homo sapiens] (Dezamizumab) Monoclonal Antibody Dezamizumab has been investigated for the treatment of AL amyloidosis.

Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade, ProteoGenix, PX-TA1323

Description of Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade General information on Anti-ganglioside GD2[Homo sapiens] (Dinutuximab) Monoclonal Antibody Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.

Disitamab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade, ProteoGenix, PX-TA1574

Description of Disitamab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade Disitamab Biosimilar: A Revolutionary Antibody Targeting ERBB2, EGFR2, and CD340 Disitamab Biosimilar, also known as Anti-ERBB2, EGFR2, CD340 mAb, is a highly potent monoclonal antibody that has gained significant attention in the field of cancer research. This biosimilar is specifically designed to target three important therapeutic targets – ERBB2, EGFR2, and CD340 – and has shown promising results in preclinical studies for the treatment of various cancers. In this article, we will explore the structure, activity, and potential applications of Disitamab Biosimilar in detail. Structure of Disitamab Biosimilar Disitamab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced in a laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its specific targets, while the constant region determines the antibody’s effector functions. The antibody’s variable region is designed to specifically target three proteins – ERBB2, EGFR2, and CD340 – which are overexpressed in many types of cancer. This targeting mechanism makes Disitamab Biosimilar highly specific and selective, reducing the risk of off-target effects. Activity of Disitamab Biosimilar The primary activity of Disitamab Biosimilar is to inhibit the activity of ERBB2, EGFR2, and CD340 proteins, which are known to play a crucial role in cancer growth and progression. ERBB2 and EGFR2 are members of the epidermal growth factor receptor (EGFR) family, which are involved in cell proliferation, survival, and differentiation. CD340, also known as mesothelin, is a protein found on the surface of many cancer cells and is associated with tumor growth and metastasis. By binding to these proteins, Disitamab Biosimilar blocks their signaling pathways and prevents them from promoting cancer cell growth. This inhibition can lead to the death of cancer cells or slow down their growth, making Disitamab Biosimilar a potential therapeutic option for various types of cancer. Potential Applications of Disitamab Biosimilar Disitamab Biosimilar has shown promising results in preclinical studies for the treatment of different types of cancer, including breast, lung, ovarian, and pancreatic cancer. It has also been evaluated in combination with other cancer therapies, such as chemotherapy and radiation therapy, and has shown enhanced efficacy. One of the most significant advantages of Disitamab Biosimilar is its potential to overcome resistance to other targeted therapies. Many cancers develop resistance to currently available treatments, making them challenging to treat. However, Disitamab Biosimilar targets multiple proteins, making it less likely for cancer cells to develop resistance to it. In addition to its therapeutic potential, Disitamab Biosimilar is also being studied for diagnostic purposes. As it specifically targets ERBB2, EGFR2, and CD340, it can be used to detect the presence of these proteins in cancer cells, aiding in cancer diagnosis and monitoring treatment response. Conclusion Disitamab Biosimilar is a highly promising antibody that targets three important proteins involved in cancer growth and progression. Its unique structure and mechanism of action make it a potential therapeutic option for various types of cancer, including those that are resistant to currently available treatments. As research on Disitamab Biosimilar continues, it may prove to be a valuable addition to the arsenal of cancer therapies.

Domagrozumab Biosimilar – Anti-MSTN , GDF8 mAb – Research Grade, ProteoGenix, PX-TA1426

Description of Domagrozumab Biosimilar - Anti-MSTN , GDF8 mAb - Research Grade General information on Anti-MSTN /GDF8[Homo sapiens] (Domagrozumab) Monoclonal Antibody Domagrozumab is investigated for the treatment of Duchenne muscular dystrophy (DMD).

Domvanalimab Biosimilar – Anti-TIGIT mAb – Research Grade, ProteoGenix, PX-TA1659

Description of Domvanalimab Biosimilar - Anti-TIGIT mAb - Research Grade Introduction Domvanalimab Biosimilar, also known as Anti-TIGIT mAb, is a monoclonal antibody that has been developed as a biosimilar to the original TIGIT antibody. This biosimilar has been designed to target a specific protein, TIGIT, which has been identified as a potential therapeutic target in various diseases. In this article, we will provide a detailed scientific description of the structure, activity, and potential applications of Domvanalimab Biosimilar. Structure of Domvanalimab Biosimilar Domvanalimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, which means it has been engineered to closely resemble a human antibody. It consists of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its target, TIGIT, while the constant region determines the antibody’s effector functions. Activity of Domvanalimab Biosimilar TIGIT is a protein that is expressed on the surface of immune cells, including T cells, natural killer cells, and regulatory T cells. It interacts with another protein called PVR, which is found on the surface of tumor cells and immune cells. This interaction between TIGIT and PVR leads to the suppression of immune responses, allowing tumors to evade the immune system and grow. Domvanalimab Biosimilar works by binding to TIGIT and blocking its interaction with PVR, thereby restoring the immune system’s ability to recognize and attack tumor cells. Applications of Domvanalimab Biosimilar Domvanalimab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for its potential therapeutic applications. Some of the diseases that may benefit from this biosimilar include: 1. Cancer: TIGIT has been identified as a potential therapeutic target in various types of cancer, including lung cancer, breast cancer, and melanoma. By blocking TIGIT, Domvanalimab Biosimilar may enhance the anti-tumor immune response and improve the effectiveness of cancer treatments. 2. Autoimmune diseases: TIGIT has also been implicated in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. By inhibiting TIGIT, Domvanalimab Biosimilar may help to regulate the immune response and reduce inflammation in these conditions. 3. Infectious diseases: TIGIT has been found to play a role in the immune response to viral infections, such as hepatitis B and HIV. Domvanalimab Biosimilar may potentially be used as an adjuvant therapy to enhance the body’s immune response and improve the efficacy of antiviral treatments. 4. Transplant rejection: TIGIT has been shown to be involved in the suppression of immune responses in transplant rejection. By blocking TIGIT, Domvanalimab Biosimilar may help to prevent the rejection of transplanted organs. Conclusion In summary, Domvanalimab Biosimilar is a promising monoclonal antibody that has been developed as a biosimilar to the original TIGIT antibody. Its structure, activity, and potential applications make it a valuable therapeutic agent in the treatment of various diseases. Further research and clinical trials will help to determine the full potential of this biosimilar in improving patient outcomes.

Donanemab Biosimilar – Anti-APP mAb – Research Grade, ProteoGenix, PX-TA1549

Description of Donanemab Biosimilar - Anti-APP mAb - Research Grade What is Donanemab? Donanemab is a humanized monoclonal antibody (IgG1) derived from mouse mE8-IgG2a specifically for the treatment of Alzheimer’s disease (AD). It has a unique mechanism of action that targets and clears a protein called amyloid-beta (Aβ). The latter is responsible for the build-up of plaques in the brains of Alzheimer’s patients, causing neuronal damage and dementia. Targeted Approach: Donanemab is a plaque-binding antibody, that provides a unique approach to treating the disease. It is designed to specifically target the N-truncated pyroglutamate amyloid beta peptide at position 3 (pGlu3-Aβ, AβpE3), which is a specific form of pyroglutamate of the amyloid beta protein. By binding to these plaques, donanemab promotes their clearance, potentially reducing the burden on neurons and slowing disease progression. Donanemab facilitates their clearance from the brain by selectively binding to these plaques, addressing a key feature of Alzheimer’s disease pathology. This targeted approach distinguishes Donanemab from other treatments that focus solely on preventing plaque deposition or growth. Because it acts directly to clear existing amyloid plaques by specifically binding to them, it has a high affinity for deposited plaques. This mechanism of action offers a novel therapeutic strategy in the fight against Alzheimer’s disease. Mechanism of Action: Targeting Amyloid-Beta: Selectively binds to aggregated forms of amyloid-beta. Promotion Amyloid Clearance: induction of microglial-mediated clearance. Fc Receptor Activation: Enhancement of the activation of microglia and facilitates the clearance via Fc fragment – Fc receptor binding. Activation of Phagocytosis: Internalization of the Donanemab-amyloid complex by microglia cells through the mechanism of phagocytosis leading to effective removal of amyloid-β plaques from the brain tissue. Reduction of Aβ Burden: Alleviate the associated neurotoxic effects and potentially slow down the progression of cognitive decline in patients with AD. Clinical Efficacy: Donanemab represents an innovative approach to the treatment of Alzheimer’s disease. Its mechanism of action, which focuses on clearing Aβ plaques, offers an alternative strategy to previously approved treatments. Donanemab has the potential to offer Alzheimer’s patients a more specialized and effective treatment option by directly targeting the underlying disease. Clinical trials of Donanemab have shown encouraging results for AD patients in terms of cognitive development and functional outcomes. In a study of 1,736 people, Donanemab showed a significant 35% reduction in mental decline over 18 months compared to the placebo group. Participants also experienced a significant 40% reduction in loss of ability to perform daily activities. These encouraging clinical results demonstrate the potential efficacy of donanemab in improving cognitive function and maintaining independence in patients with Alzheimer’s disease. As any therapeutic intervention must take safety into account. Throughout its development, Donanemab has undergone rigorous safety evaluations. Because of its humanized antibody structure, it reduces the possibility of negative side effects, making it well tolerated by patients. This improved safety profile is critical to the commercialization and future use of Donanemab as a therapeutic option for Alzheimer’s disease. Conclusion Donanemab represents a significant advancement in the treatment of Alzheimer’s disease. Through its targeted approach of selectively binding and clearing amyloid-beta plaques, Donanemab holds promise for slowing disease progression and improving cognitive function in Alzheimer’s disease patients.